Findings from CALGB/SWOG 80702 and ALTAIR studies were presented during 2025 ASCO GI Cancers Symposium, held January 23-25th. Click on the trial titles to view full articles.
CALGB/SWOG 80702 (NCT01150045)
- Positive ctDNA status is linked to worse DFS in stage III resected colon cancer, but celecoxib improves outcomes in ctDNA-positive patients.
- ctDNA status is prognostic for DFS and OS, and predictive of celecoxib benefit in the CALGB/SWOG 80702 trial.
- Celecoxib did not significantly affect DFS in ctDNA-negative patients, indicating its benefit is specific to ctDNA-positive individuals.
- Ongoing analyses aim to further elucidate ctDNA’s predictive value for adjuvant FOLFOX duration in this patient population.
- While trifluridine/tipiracil (Lonsurf) did not significantly improve disease-free survival (DFS) over placebo in the full population of patients with colorectal cancer (CRC) with molecular residual disease post-curative resection, it provided a clinically meaningful benefit for those with stage IV disease.
